Skip to main content
NCBI home page
Trials logoLink to Trials
. 2022 Oct 5;23:852. doi: 10.1186/s13063-022-06814-8

Correction: Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

The AIMM Trial Group:, Alaa Abouhajar 1, Lisa Alcock 2, Theophile Bigirumurame 3, Penny Bradley 4, Laura Brown 5, Ian Campbell 4, Silvia Del Din 2, Julie Faitg 5, Gavin Falkous 5, Grainne S Gorman 5,6, Rachel Lakey 1, Robert McFarland 5,6, Jane Newman 5, Lynn Rochester 2, Vicky Ryan 3, Hesther Smith 4, Alison Steel 1, Renae J Stefanetti 5, Huizhong Su 5, Robert W Taylor 5,6, Naomi J P Thomas 5,6,✉, Helen Tuppen 5, Amy E Vincent 5, Charlotte Warren 5, Gillian Watson 1
PMCID: PMC9533513  PMID: 36199067

Correction: Trials 23, 789 (2022)

https://doi.org/10.1186/s13063-022-06544-x

Following the publication of the original article [1], we were notified that the name of the 7th author has been incorrectly spelled.

Originally published name: Sylvia Del Din

Corrected name: Silvia Del Din

The original article has been corrected.

Reference

  • 1.The AIMM Trial Group Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. Trials. 2022;23:789. doi: 10.1186/s13063-022-06544-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES